Stressing the development of small molecules targeting HSP90.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 24166908.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2571.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Inhibitors of the molecular chaperone HSP90 have been in clinical development as anticancer agents since 1999. Recent clinical studies, including the work of Saif and colleagues in this issue of Clinical Cancer Research, demonstrate that significant progress has been made in overcoming the obstacles preventing regulatory approval.
Medical subject headings
- Adenine
- Antineoplastic Agents
- Neoplasms
- Pyridines